Table 5.

The influence of cyclophosphamide or ciclosporin on metabolism in IMN patients with coexisting DM

	DM
	CTX	CsA	p-value
Accumulative GC dose (g)	6.2 ± 2.5	2.2 ± 0.9	< 0.001
Fasting blood glucose
Pre-treatment FBG (mmol/L)	9.6 ± 3.4	8.4 ± 4.5	0.516
Post-treatment FBG (mmol/L)	5.8 ± 1.5	5.9 ± 1.5	0.826
Changes of FBG (mmol/L)	−2.8(−5.0, −1.0)	−1.2(−3.6, 0.2)	0.110
Goal Attainment Rates of FBG (%)	62.5%	70%	0.701
Uric acid
Pre-treatment uric acid (μmol/L)	376.5 ± 63.9	428.2 ± 123.4	0.272
Post-treatment uric acid (μmol/L)	351.1 ± 67.5	418.7 ± 142.1	0.213
Changes of uric acid (μmol/L)	−12.5(−101.3,56.5)	8.5(− 107.9,75.8)	0.672
Goal Attainment Rates of uric acid (%)	87.5%	70%	0.334
Cholesterol
Pre-treatment CHOL (mmol/L)	7.2 ± 2.4	8.7 ± 3.0	0.196
Post-treatment CHOL (mmol/L)	4.6 ± 0.8	4.6 ± 2.8	0.929
Changes of CHOL (mmol/L)	−2.0(−5.6,0.1)	−3.5(−6.2, −1.2)	0.940
Goal Attainment Rates of CHOL (%)	87.5%	55%	0.105
Triglyceride
Pre-treatment TG (mmol/L)	3.2 ± 2.7	3.3 ± 1.7	0.898
Post-treatment TG (mmol/L)	1.8 ± 0.8	2.2 ± 1.0	0.391
Changes of TG (mmol/L)	−0.9(−2.3, −0.3)	−0.6(− 2.5,0)	0.709
Goal Attainment Rates of TG (%)	50%	40%	0.629
High density lipoprotein
Pre-treatment HDL (mmol/L)	1.5 ± 0.6	1.5 ± 0.4	0.982
Post-treatment HDL (mmol/L)	1.4 ± 0.5	1.5 ± 0.6	0.617
Changes of HDL (mmol/L)	−0.2(−0.3,0)	0(−0.3,0)	0.533
Goal Attainment Rates of HDL (%)	50%	60%	0.629
Low density lipoprotein
Pre-treatment LDL (mmol/L)	4.4 ± 1.6	5.4 ± 2.0	0.221
Post-treatment LDL (mmol/L)	2.7 ± 0.7	2.3 ± 2.0	0.634
Changes of LDL (mmol/L)	−1.7(−3.5,0.2)	−3.7(−4.6, −1.0)	0.784
Goal Attainment Rates of LDL (%)	100%	60%	0.063

Data were expressed as mean ± SD (standard deviation), medians (interquartile range), or percentage (%)

GC glucocorticoid, FBG fasting blood glucose, CHOL cholesterol, TG triglyceride, HDL high density lipoprotein, LDL low density lipoprotein, CTX cyclophosphamide, CsA ciclosporin